Feldmann Marc, Steinman Lawrence
Kennedy Institute of Rheumatology, Faculty of Medicine, Imperial College School of Medicine, ARC Building, 1 Aspenlea Road, London W6 8LH, UK.
Nature. 2005 Jun 2;435(7042):612-9. doi: 10.1038/nature03727.
A better understanding of the molecules involved in immune responses has identified many potential targets for the treatment of autoimmune diseases. But although successful therapies have been found for immune disorders in animal studies, few have passed the much harder test of treating human diseases. So far, non-antigen-specific approaches, such as the blocking of tumour-necrosis factor, are achieving some success but the same is not true for antigen-specific approaches. Future therapies will probably include both non-antigen-specific strategies that target cytokines (cell-cell signalling molecules) or block the molecules that stimulate immune responses, and antigen-specific therapies that induce tolerance to self antigens.
对免疫反应中涉及分子的更深入理解,已确定了许多治疗自身免疫性疾病的潜在靶点。然而,尽管在动物研究中已发现针对免疫紊乱的成功疗法,但很少有疗法通过治疗人类疾病这项困难得多的测试。到目前为止,非抗原特异性方法,如阻断肿瘤坏死因子,已取得了一些成效,但抗原特异性方法并非如此。未来的治疗可能既包括针对细胞因子(细胞间信号分子)或阻断刺激免疫反应分子的非抗原特异性策略,也包括诱导对自身抗原产生耐受性的抗原特异性疗法。